A monoclonal antibody that the FDA approved last year to prevent chronic and episodic migraine has now received approval to treat episodic cluster headache in adults. The drug blocks calcitonin gene-related peptide ligand—a potent vasodilator that modulates nociceptive trigeminal neurons involved in the pathophysiology of cluster headaches. Patients can self-inject galcanezumab, marketed as Emgality.
Sancar F. Episodic Cluster Headache Antibody Therapy. JAMA. 2019;322(3):199. doi:10.1001/jama.2019.9917
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: